Andrew Kuykendall

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial”.

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Nature Medicine(2025)10.1038/s41591-025-03572-3

N/A

0.664DataRank · unranked

40 citations

Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron T. Gerds +23 more

Survival following allogeneic transplant in patients with myelofibrosis

Blood Advances(2020)10.1182/bloodadvances.2019001084

N/A

0DataRank · unranked

97 citations

Karen K. Ballen, Kwang Woo Ahn, Zhen‐Huan Hu, Haris Ali, Murat O. Arcasoy +63 more

A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0276

N/A

0DataRank · unranked

34 citations

Anna Ritá Migliaccio, Heidi Kosiorek, Rupali Bhave, Jeanne Palmer, Andrew Kuykendall +29 more

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood(2024)10.1182/blood.2024025802

N/A

0DataRank · unranked

25 citations

Giovanni Barosi, Francesco Passamonti, Juan Carlos Hernández‐Boluda, Prithviraj Bose, Konstanze Döhner +33 more

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms

American Journal of Hematology(2024)10.1002/ajh.27282

N/A

0DataRank · unranked

5 citations

Lucia Mazzacurati, Tegan M. Rowsell, Nathan P. Horvat, Narmin E. Amin, Guolin Zhang +8 more

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Leukemia(2025)10.1038/s41375-025-02515-8

N/A

0DataRank · unranked

13 citations

Xiaoli Mi, Bin Lü, Andrew Kuykendall, David A. Sallman, Manish R. Patel +16 more